3.36
price up icon0.00%   0.00
pre-market  Pre-market:  3.27   -0.09   -2.68%
loading
Arbutus Biopharma Corp stock is traded at $3.36, with a volume of 551.42K. It is up +0.00% in the last 24 hours and down -6.41% over the past month. Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$3.36
Open:
$3.37
24h Volume:
551.42K
Relative Volume:
0.56
Market Cap:
$643.54M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.6364
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+4.35%
1M Performance:
-6.41%
6M Performance:
-2.89%
1Y Performance:
+0.00%
1-Day Range:
Value
$3.33
$3.43
1-Week Range:
Value
$3.236
$3.535
52-Week Range:
Value
$2.705
$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name
Name
Arbutus Biopharma Corp
Name
Phone
604-419-3200
Name
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Name
Employee
44
Name
Twitter
@arbutusbio
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ABUS's Discussions on Twitter

Compare ABUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ABUS
Arbutus Biopharma Corp
3.36 660.77M 12.99M -74.39M -78.92M -0.44
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-02-22 Upgrade Jefferies Hold → Buy
Feb-25-21 Initiated Jefferies Hold
Dec-17-20 Initiated H.C. Wainwright Buy
Jul-27-20 Resumed JMP Securities Mkt Outperform
Jul-24-20 Downgrade Robert W. Baird Outperform → Neutral
May-19-20 Upgrade Wedbush Neutral → Outperform
Mar-06-20 Upgrade Chardan Capital Markets Neutral → Buy
Feb-20-20 Initiated Robert W. Baird Outperform
Feb-05-20 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Oct-07-19 Reiterated B. Riley FBR Buy
Oct-04-19 Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18 Upgrade B. Riley FBR Neutral → Buy
Oct-15-18 Upgrade Wedbush Underperform → Neutral
Oct-12-18 Reiterated Chardan Capital Markets Buy
Jul-06-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Mar-19-18 Resumed Chardan Capital Markets Buy
Mar-19-18 Downgrade Wedbush Outperform → Neutral
Jan-05-18 Initiated B. Riley FBR, Inc. Buy
Apr-04-17 Upgrade Chardan Capital Markets Neutral → Buy
Feb-01-17 Reiterated Wedbush Outperform
Dec-13-16 Downgrade Chardan Capital Markets Buy → Neutral
Nov-30-16 Upgrade Chardan Capital Markets Neutral → Buy
View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

pulisher
May 29, 2025

Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 29, 2025
pulisher
May 22, 2025

Northern Trust Corp Has $4.35 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 22, 2025
pulisher
May 18, 2025

Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo

May 18, 2025
pulisher
May 18, 2025

Mercer Global Advisors Inc. ADV Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 18, 2025
pulisher
May 18, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 15, 2025

Arbutus: Q1 Earnings Snapshot - CT Insider

May 15, 2025
pulisher
May 14, 2025

Arbutus Biopharma Corp Reports Q1 2025 Earnings: Revenue at $1.8 Million, EPS Misses Estimate with $0.13 Loss - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Arbutus Biopharma (ABUS) Reports Mixed Q1 Results - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Arbutus (ABUS) Reports Lower Q1 Revenue Amid Promising Treatment Progress | ABUS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 13, 2025

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

May 13, 2025
pulisher
May 10, 2025

Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 - MyChesCo

May 10, 2025
pulisher
May 08, 2025

Wells Fargo & Company MN Acquires 21,768 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 08, 2025
pulisher
May 07, 2025

Arbutus Biopharma (ABUS) Showcases Promising Data on Imdusiran and AB-101 | ABUS Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Arbutus Presents Clinical Trial Data from its Two HBV - GlobeNewswire

May 07, 2025
pulisher
May 06, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Barclays PLC - Defense World

May 06, 2025
pulisher
May 05, 2025

Invesco Ltd. Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 05, 2025
pulisher
May 02, 2025

Arbutus Biopharma Corp (ABUS) is a good investment, but the stock may be overvalued - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Arbutus Biopharma Corp (ABUS) With A Potential Upside Of More Than -139.44% - Stocksregister

May 01, 2025
pulisher
May 01, 2025

Arbutus Biopharma Corp (ABUS) looking to reclaim success with recent performance - Sete News

May 01, 2025
pulisher
May 01, 2025

Legal & General Group Plc Has $388,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Arbutus Biopharma Corp [ABUS] Insider Activity: An Update for Investors - knoxdaily.com

Apr 30, 2025
pulisher
Apr 28, 2025

Arbutus Biopharma Corp expected to post a loss of 10 cents a shareEarnings Preview - TradingView

Apr 28, 2025
pulisher
Apr 26, 2025

Stock Market Recap: Arbutus Biopharma Corp (ABUS) Concludes at 3.12, a -1.58 Surge/Decline - DWinneX

Apr 26, 2025
pulisher
Apr 25, 2025

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Apr 25, 2025
pulisher
Apr 24, 2025

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo

Apr 24, 2025
pulisher
Apr 23, 2025

Arbutus Biopharma Corp (ABUS)’s stock price in review: A technical analysis - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 21, 2025

Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 21, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Buys 16,484 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Corebridge Financial Inc. Has $238,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

KLP Kapitalforvaltning AS Invests $84,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 11, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today

Apr 02, 2025
pulisher
Apr 01, 2025

Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Arbutus Biopharma Corp (NASDAQ: ABUS) – An Analysis Is What You Need - stocksregister.com

Apr 01, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Mar 31, 2025
pulisher
Mar 30, 2025

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN

Mar 30, 2025
pulisher
Mar 30, 2025

Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World

Mar 29, 2025

Arbutus Biopharma Corp Stock (ABUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Cap:     |  Volume (24h):